These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 24472711)

  • 1. The economics of bladder cancer: costs and considerations of caring for this disease.
    Svatek RS; Hollenbeck BK; Holmäng S; Lee R; Kim SP; Stenzl A; Lotan Y
    Eur Urol; 2014 Aug; 66(2):253-62. PubMed ID: 24472711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
    Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
    Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effective treatment of low-risk carcinoma not invading bladder muscle.
    Green DA; Rink M; Cha EK; Xylinas E; Chughtai B; Scherr DS; Shariat SF; Lee RK
    BJU Int; 2013 Mar; 111(3 Pt B):E78-84. PubMed ID: 22958598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
    Tandogdu Z; Lewis R; Duncan A; Penegar S; McDonald A; Vale L; Shen J; Kelly JD; Pickard R; N Dow J; Ramsay C; Mostafid H; Mariappan P; Nabi G; Creswell J; Lazarowicz H; McGrath J; Taylor E; Clark E; Maclennan G; Norrie J; Hall E; Heer R;
    BMJ Open; 2019 Sep; 9(9):e022268. PubMed ID: 31481549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of second opinion pathology in the definitive management of patients with bladder carcinoma.
    Coblentz TR; Mills SE; Theodorescu D
    Cancer; 2001 Apr; 91(7):1284-90. PubMed ID: 11283928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The health economics of bladder cancer: a comprehensive review of the published literature.
    Botteman MF; Pashos CL; Redaelli A; Laskin B; Hauser R
    Pharmacoeconomics; 2003; 21(18):1315-30. PubMed ID: 14750899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of tumor markers in bladder cancer surveillance.
    Hong YM; Loughlin KR
    Urology; 2008 Jan; 71(1):131-5. PubMed ID: 18242381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
    Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
    BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies.
    Richards KA; Smith ND; Steinberg GD
    J Urol; 2014 Jun; 191(6):1655-64. PubMed ID: 24518761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The health economics of bladder cancer: an updated review of the published literature.
    Yeung C; Dinh T; Lee J
    Pharmacoeconomics; 2014 Nov; 32(11):1093-104. PubMed ID: 25056838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system.
    Feifer A; Xie X; Brophy JM; Segal R; Kassouf W
    Urology; 2010 Sep; 76(3):652-6. PubMed ID: 20394970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
    Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
    Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802.
    Tester W; Caplan R; Heaney J; Venner P; Whittington R; Byhardt R; True L; Shipley W
    J Clin Oncol; 1996 Jan; 14(1):119-26. PubMed ID: 8558186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical advances in bladder cancer: at what cost?
    Johnson DC; Greene PS; Nielsen ME
    Urol Clin North Am; 2015 May; 42(2):235-52, ix. PubMed ID: 25882565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
    Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
    Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
    Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. So much cost, such little progress.
    Bryan RT; Kirby R; O'Brien T; Mostafid H
    Eur Urol; 2014 Aug; 66(2):263-4. PubMed ID: 24598013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 28.